Overview of response to chemotherapy in advanced-stage large cell neuroendocrine carcinoma disease
| First author [reference] | Design | Panel review (pathologists n) | Inclusion period | NSCLC chemotherapy | SCLC chemotherapy | ||||
| Patients n | ORR % | OS months | Patients n | ORR % | OS months | ||||
| Le Treut [11] | P | Yes (?) | 2004–2009 | 29 | 34 | 8.0 | |||
| Niho [12] | P | Yes (6) | 2005–2011 | 30 | 47 | 12.6 | |||
| Metro [20] | R | No revision | Unclear | 37 | 43 | 8.4 | |||
| Naidoo [19] | R | Yes (3) | 2006–2013 | 11# | 0# | 19.5 | 26¶ | 37 | 8.3 |
| Sun [18] | R | Yes (?) | 2001–2010 | 34+ | 50 | 9.2 | 11 | 73 | 16.5 |
| Rossi [17] | R | Yes (3) | 1990–2004 | 15 | 0 | 21 | 12 | 50 | 51 |
| Fujiwara [21] | R | No (1) | 1999–2006 | 9§ | 77 | 13 | 46 | ||
| Derks (present study) | R | Yes (3) | 2003–2012 | 60 (NSCLC) | 8.5 | 48 | 33 | 6.7 | |
| 20 (pemetrexed-NSCLC) | 5.9 | ||||||||
Studies including patients treated with chemoradiotherapy are not shown. NSCLC: nonsmall cell lung carcinoma; SCLC: small cell lung carcinoma; ORR: objective response rate; OS: overall survival; P: prospective; R: retrospective. #: four patients were evaluated according to response evaluation criteria in solid tumours (RECIST), including temozolomide (n=2), pemetrexed (n=1) and platinum combined with everolimus (n=1); ¶: 19 patients were evaluated according to RECIST criteria; +: including gemcitabine–platinum (n=17), taxane–platinum (n=4), tyrosine kinase inhibitor (n=2) and other platinum (n=11); §: taxane combined with platinum (n=7), taxane monotherapy (n=1) and platinum–vinorelbine (n=1).